Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02741830 · ClinicalTrials.gov registry record
Uterosacral Ligament Suspension vs Robotic Sacrocolpopexy
A clinical trial, sponsored by TriHealth.
- Completed
- Registry status
- 186
- Enrollment target
NCT02741830: Completed study, sponsored by TriHealth.
NCT02741830 is a clinical trial that has completed, run by TriHealth. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02741830 has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
This cross sectional, two cohort study seeks to investigate both anatomic outcome and subjective, functional outcome of uterosacral ligament suspension versus robotic sacrocolpopexy and compare patient satisfaction, bladder function, sexual function and complication rate for each procedure.This study will provide a better understanding about the durability of these procedures and long term complication.
Primary Outcome
This is a binary outcome, and success is defined as answering "No" to question #3 on the Pelvic Organ Prolapse Distress Inventory (PFDI-20) questionnaire, as well as the absence of any reoperation or pessary use for pelvic organ prolapsed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2018-10-16 |
What the finished NCT02741830 record still lists
NCT02741830 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02741830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02741830 about?
NCT02741830 is a clinical study titled "Uterosacral Ligament Suspension vs Robotic Sacrocolpopexy". This cross sectional, two cohort study seeks to investigate both anatomic outcome and subjective, functional outcome of uterosacral ligament suspension versus robotic sacrocolpopexy and compare patient satisfaction, bladder function, sexual function and complication rate for each procedure.This stud...
What is the current status of trial NCT02741830?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2016-04-07. Estimated completion is 2018-10-16.
Who is sponsoring clinical trial NCT02741830?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI